New device may reduce radiation exposure to patients with liver cancer
the ONA take:
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer undergoing intra-arterial therapy (IAT), according to a report to be presented at the Radiological Society of North America annual meeting in Chicago.
In a clinical trial, Jean-Francois Geschwind, MD, and fellow researchers at Johns Hopkins University School of Medicine and Kimmel Cancer Center used the device on 50 patients, the researchers found that it was able to reduce exposure by up to 80 percent compared to standard X-ray platforms for IAT. In addition, AlluraClarity produced images that were just as clear as the standard system.
Dr. Geschwind believes that the novel platform will be especially useful in patients who require repeat therapy and are especially vulnerable to radiation such as children, as well as physicians who are regularly exposed to radiation procedures.
AlluraClarity uses a series of real-time image processing algorithms in order to achieve high quality images that require lower radiation power. It is developed by Philips Healthcare.
AlluraClarity has the potential to reduce radiation exposure in patients with liver cancer.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|